Primary and secondary outcomes and bronchiectasis symptoms assessed at baseline and after treatment by intent-to-treat analysis
| Fluticasone group (n = 43, 23F) | Placebo group (n = 43, 34F) | p value* | Mean (95% CI) difference | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After treatment | Baseline | After treatment | |||||
| Unless otherwise stated, data are shown as mean (SD). | ||||||||
| *p value for between group comparison on post-treatment data. | ||||||||
| †Median (interquartile range). | ||||||||
| Primary outcome parameters | ||||||||
| 24 hour sputum volume (ml)† | 10 (5–25) | 5 (2–20) | 10 (5–20) | 5 (3–20) | 0.72 | −1.0 (−6.56 to 4.56) | ||
| Exacerbation frequency(/year)† | 4 (2–5) | 2 (1–4) | 2 (1–4) | 2 (1–3) | 0.41 | 0.42 (−0.59 to 1.43) | ||
| Secondary outcome parameters | ||||||||
| Sputum purulence score | 6.1 (2.0) | 5.7 (2.7) | 6.0 (1.8) | 5.5 (2.7) | 0.73 | −0.21 (−1.39 to 0.97) | ||
| FEV1 % predicted | 74.1 (29.4) | 74.4 (31.5) | 74.4 (29.2) | 74.4 (29.9) | 1.00 | −0.02 (−13.19 to 13.14) | ||
| FVC % predicted | 83.1 (23.6) | 83.1 (23.4) | 85.0 (22.6) | 85.9 (23.3) | 0.58 | 2.81 (−7.2 to 12.82) | ||
| % of patients with | ||||||||
| Cough | 76.7 | 60.5 | 93.0 | 81.4 | 0.03 | |||
| Dyspnoea | 16.3 | 2.3 | 23.3 | 4.7 | 1.00 | |||
| Haemoptysis | 39.5 | 9.3 | 51.2 | 4.7 | 0.68 | |||
| Chest pain | 32.6 | 18.6 | 41.9 | 16.3 | 0.78 | |||
| Wheezing | 39.5 | 23.3 | 46.5 | 20.9 | 0.80 | |||
| Fatigue | 74.4 | 55.8 | 65.1 | 69.8 | 0.18 | |||